Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ibalisumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarz
    TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarz

    18 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/18/2848020/0/en/TaiMed-Biologics-and-AcedrA-BioPharmaceuticals-Partner-to-Commercialize-Trogarzo-Ibalizumab-uiyk-in-the-Middle-East-and-North-Africa-Region.html

    GLOBENEWSWIRE
    18 Mar 2024
    Share Share
    Theratechnologies Submits sBLA for Trogarzo IM Method of Administration to FDA
    Theratechnologies Submits sBLA for Trogarzo IM Method of Administration to FDA

    02 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/02/2802599/0/en/Theratechnologies-Submits-sBLA-for-Trogarzo-Intramuscular-IM-Method-of-Administration-to-FDA.html

    GLOBENEWSWIRE
    02 Jan 2024
    Share Share
    Theratechnologies' Biologic Trogarzo (ibalizumab) Receives Approval in the U.S.
    Theratechnologies' Biologic Trogarzo (ibalizumab) Receives Approval in the U.S.

    12 Dec 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761065

    FDA
    12 Dec 2023
    Share Share
    Theratechnologies' Biologic Trogarzo (Ibalizumab uiyk) Receives Approval in the U.S.
    Theratechnologies' Biologic Trogarzo (Ibalizumab uiyk) Receives Approval in the U.S.

    03 Oct 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761065

    FDA
    03 Oct 2022
    Share Share
    Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV)
    Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV)

    03 Oct 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/10/03/2527271/0/en/Theratechnologies-Trogarzo-Approved-by-FDA-for-30-Second-Intravenous-IV-Push-Simplifying-HIV-Treatment-for-Heavily-Treatment-Experienced-Population.html

    GLOBENEWSWIRE
    03 Oct 2022
    Share Share
    Theratechnologies Announces Ibalizumab Inhibits HIV-2 In Vitro
    Theratechnologies Announces Ibalizumab Inhibits HIV-2 In Vitro

    06 Jul 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/07/06/2057853/0/en/Theratechnologies-Announces-Ibalizumab-Inhibits-HIV-2-In-Vitro.html#:~:text=(Theratechnologies)%20(TSX%3A%20TH,and%20group%20B%20HIV%2D2.

    GLOBENEWSWIRE
    06 Jul 2020
    Share Share